Marinus Pharmaceuticals Inc (MRNS): Are Hedge Funds Right About This Stock?

With a general bullishness amongst the heavyweights, specific money managers were breaking ground themselves. Iguana Healthcare Management, managed by Stuart Weisbrod, initiated the most valuable position in Marinus Pharmaceuticals Inc (NASDAQ:MRNS). Iguana Healthcare Management had $0.6 million invested in the company at the end of the quarter. William Leland Edwards’s Palo Alto Investors also made a $0.5 million investment in the stock during the quarter. The following funds were also among the new MRNS investors: Peter Muller’s PDT Partners and Gavin Saitowitz and Cisco J. del Valle’s Springbok Capital.

Let’s check out hedge fund activity in other stocks similar to Marinus Pharmaceuticals Inc (NASDAQ:MRNS). We will take a look at Pure Cycle Corporation (NASDAQ:PCYO), Energy Focus Inc (PINK:EFOI), TRACON Pharmaceuticals Inc (NASDAQ:TCON), and Xenon Pharmaceuticals Inc (NASDAQ:XENE). This group of stocks’ market values are similar to MRNS’s market value.

As you can see these stocks had an average of 6.75 hedge funds with bullish positions and the average amount invested in these stocks was $22 million. That figure was $5 million in MRNS’s case. Pure Cycle Corporation (NASDAQ:PCYO) is the most popular stock in this table. On the other hand TRACON Pharmaceuticals Inc (NASDAQ:TCON) is the least popular one with only 5 bullish hedge fund positions. Marinus Pharmaceuticals Inc (NASDAQ:MRNS) is not the most popular stock in this group but hedge fund interest is still above average. This is a slightly positive signal but we’d rather spend our time researching stocks that hedge funds are piling on. In this regard PCYO might be a better candidate to consider a long position.